vTv Therapeutics Inc. - VTVT Accounting Value per Share

Symbol and logo of brand vTv Therapeutics (VTVT)

The lack of revenue and previous research pauses are already priced into vTv Therapeutics Inc. (VTVT) quotes. Future inflows are based on the commercialization of type 1 diabetes therapy and psoriasis treatment. Fluctuations in the book value per share confirm the net asset trend, where the latest mark stands at 20.12. Prospects for a market breakthrough solidify the status of TTP399 as an innovative oral agent supported by the FDA and G42 Healthcare.

VTVT vTv Therapeutics Inc Share Book Value (07/04/2022 - 10/30/2026)

Summary analytical data breakdowns for vTv Therapeutics, Inc. (VTVT)

- share price and expert price forecast:
Stock Quotes vTv Therapeutics Inc|VTVT - Price Target Chart
- issuer market value details:
Market Valuation vTv Therapeutics Inc.|VTVT - Aggregate Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share vTv Therapeutics|VTVT - Net Asset Value|Market Capitalization to Book Value Ratio vtvtherapeutics.com|VTVT - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital vTv Therapeutics Inc.|VTVT - Long-Term Debt to Capital|Short-Term Debt to Equity vTv Therapeutics Inc|VTVT - Aggregate Debt Obligations|Debt to Book Capitalization Ratio vTv Therapeutics Inc.|VTVT - Company Long-Term Liabilities|Company Short-Term Debts vTv Therapeutics|Quick Liquidity Indicator vtvtherapeutics.com
- earnings and multiples data:
VTVT - Final Profit
General company analysis:VTVT - vtvtherapeutics.com
Manufactured products of vTv Therapeutics Inc

vTv Therapeutics Inc. develops highly scalable diabetes therapies, with its primary assets concentrated in intellectual property. The trend in net book value per share reflects the residual capital value after deducting liabilities, allowing investors to assess the actual asset backing of the security and the risk of asset impairment between reporting periods through the analysis of this chart.

Competitor analysis

ASND: Accounting Value per Share|MDGL: Net Assets per Single Share|CORT (Corcept Therapeutics) - Accounting Value per Share|RYTM: Book Price of a Share|Net Assets per Single Share Akero|Metsera, Inc. - Share Book Value|Book Value per Share MLTX|CRNX (Crinetics Corp) - Accounting Value of a Share|Book Value per Share NAMS (NewAmsterdam Pharma)|Book Value per Share soleno.life SLNO|FOLD - Net Assets per Single Share|Accounting Value of a Share ETNB (89bio Inc)|Agios Pharmaceuticals Inc (AGIO) - Net Assets per Single Share|Accounting Value per Share Structure Corp|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com|Accounting Value per Share LXRX (Lexicon Pharmaceuticals, Inc.)|MBX (MBX Biosciences, Inc.) - Accounting Value of a Share|Net Assets per Single Share Altimmune Corp ALT|AARD - Accounting Value per Share|Sagimet Biosciences - Book Value per Share|Net Asset Value per Share bioagelabs.com|BMEA (Biomea Fusion) - Accounting Value per Share|QNCX: Book Price of a Share|GUTS (Fractyl) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share PLUR|Net Assets per Single Share SYBX (synlogictx.com)|Net Assets per Single Share Lipocine LPCN|Matinas BioPharma Holdings, Inc. (MTNB) - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO: Net Assets per Single Share|CTCX: Book Value per Share|LUMO - Net Assets per Share|Net Assets per Single Share Organovo|Radius Recycling Inc. (RDUS) - Net Assets per Share